Department of Clinical Pharmacology, St. Olav University Hospital, Trondheim, Norway; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Broeckers Solutions, Berlin, Germany.
Forensic Sci Int. 2020 Jun;311:110274. doi: 10.1016/j.forsciint.2020.110274. Epub 2020 Apr 3.
The introduction of new psychoactive substances (NPS) on the illicit drug market has led to major challenges for the analytical laboratories. Keeping screening methods up to date with all relevant drugs is hard to achieve and the risk of missing important findings in biological samples is a matter of concern. Aiming for an extended retrospective data analysis, diagnostic fragment ions from synthetic cannabinoids (n=251), synthetic opioids (n=88) and designer benzodiazepines (n=26) not included in our original analytical method were obtained from the crowdsourced database HighResNPS.com and converted to a personalized library in a format compatible with the analytical instrumentation. Data files from the analysis of 1314 forensic post mortem samples with an Agilent 6540 ultra high pressure liquid chromatography quadrupole time-of-flight mass spectrometry (UHPLC-QTOF-MS) performed in our laboratory from January 2014 to December 2018 were retrieved and retrospectively processed with the new personalized library. Potentially positive findings were grouped in two: The most confident findings contained MS/MS data for library match (category 1) whereas the less confident findings lacked such data (category 2). Five new category 1 findings were identified: Flubromazepam in two data files from 2015 and 2016, respectively, phenibut (4-amino-3-phenylbutyric acid) in one data file from 2015, fluorofentanyl in one data file from 2016 and cyclopropylfentanyl in one data file from 2018. Retention time matches with reference standards further strengthened these findings. A list of 35 presumably positive category 2 findings was generated. Of these, only one finding of phenibut was considered plausible after checking retention times and signal-to-noise ratios. This study shows that new compounds can be detected retrospectively in data files from QTOF-MS using an updated library containing diagnostic fragment ions. Automatic screening procedures can be useful, but a manual re-evaluation of positive findings will always be necessary.
新型精神活性物质(NPS)在非法毒品市场的引入给分析实验室带来了重大挑战。要使筛选方法与所有相关药物保持同步是很难实现的,而在生物样本中错过重要发现的风险令人担忧。本研究旨在进行扩展的回顾性数据分析,从 crowdsourced 数据库 HighResNPS.com 中获取未包含在我们原始分析方法中的合成大麻素(n=251)、合成阿片类药物(n=88)和设计苯并二氮䓬类药物(n=26)的诊断碎片离子,并将其转换为与分析仪器兼容的格式的个性化库。检索并使用新的个性化库对 2014 年 1 月至 2018 年 12 月期间在我们实验室用安捷伦 6540 超高效液相色谱四极杆飞行时间质谱(UHPLC-QTOF-MS)分析的 1314 份法医死后样本的分析数据文件进行了回顾性处理。将潜在阳性结果分为两类:最有信心的发现包含库匹配的 MS/MS 数据(类别 1),而不太有信心的发现则缺乏此类数据(类别 2)。发现了 5 个新的类别 1 发现:2015 年和 2016 年的两个数据文件中分别有氟马西泮,2015 年的一个数据文件中有苯丁氮䓬(4-氨基-3-苯基丁酸),2016 年的一个数据文件中有氟芬太尼,2018 年的一个数据文件中有环丙基芬太尼。与参比标准的保留时间匹配进一步证实了这些发现。生成了一份 35 个推测阳性类别 2 发现的列表。在这些发现中,只有在检查保留时间和信噪比后,苯丁氮䓬的一个发现被认为是合理的。本研究表明,使用包含诊断碎片离子的更新库可以在 QTOF-MS 的数据文件中进行回顾性检测新型化合物。自动筛选程序可能很有用,但总是需要对阳性发现进行手动重新评估。